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Research on the efficacy of hypnosis applications continues to grow, but there remain major gaps 
between the science and clinical practice. One challenge has been a lack of consensus on what 
applications of hypnosis are efficacious based on research evidence. In 2018, six major hypnosis 
organizations collaborated to form a Task Force for Establishing Efficacy Standards for Clinical 
Hypnosis. This paper describes a Guideline for the Assessment of Efficacy of Clinical Hypnosis 
Applications developed by the Task Force which makes ten specific recommendations. The 
guideline is intended to be a tool for those who want to assess the quality of existing evidence on 
the efficacy of clinical hypnosis for any particular indication. The paper also discusses 
methodological issues in the interpretation and implementation of these guidelines. Future papers 
will report on the other products of the Hypnosis Efficacy Task Force, such as best practice 
recommendations for outcomes research in hypnosis, and an international survey of researchers 
and clinicians on current practice and attitudes about hypnosis. 
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Guidelines for the Assessment of Efficacy of Clinical Hypnosis Applications 
There is a wealth of research on clinical applications of hypnosis. Likewise, clinical 
hypnosis is used in the treatment of a multitude of disorders and illnesses by clinicians 
worldwide. However, there is a disconnect between the scientific literature and much of clinical 
practice (Jensen et al., 2017). Many of the specific applications of this treatment modality, even 
some of the ones that are widely used in clinical practice, have still not been investigated in 
research and are therefore not supported by scientific evidence. One of the reasons for this 
disconnect is that so far there have been no widely accepted standards for establishing the 
efficacy of clinical hypnosis interventions. Although double-blind controlled trials provide 
guardrails that reduce straying far from validity, they are not feasible for hypnosis trials. To 
address this issue, the Task Force for Establishing Efficacy Standards for Clinical Hypnosis 
(from hereon, the Hypnosis Efficacy Task Force) was assembled. In this paper we present a list 
of recommendations for researchers and clinicians who plan to assess the efficacy of clinical 
applications of hypnosis in the treatment of medical and mental health disorders and symptoms. 
Healthcare providers, insurers, clinicians, and patients are looking for clear, evidence-
based recommendations about which therapies to use. The field of clinical hypnosis is now at a 
point, after nearly a century of formal scientific hypnosis research, where hundreds of research 
trials and case studies investigating the effectiveness of hypnosis-based interventions for the 
treatment of various symptoms and conditions have been published (for recent reviews, see e.g., 
Madden et al., 2016; Carlson, et al., 2018; Kendrick et al., 2016; Fisch et al., 2017; Catsaros & 
Wendland, 2020). Thus, it is reasonable to expect researchers to be able to formulate evidence-
based recommendations about clinical applications of hypnosis. Such recommendations, based 
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on the systematic evaluation of accumulated evidence, are integral for making decisions 
regarding the adoption of effective interventions. The standards for assessing the efficacy of 
interventions have evolved considerably since the emergence of debate on evidence-based 
practice and empirically supported interventions in the 1990s (Evidence-Based Medicine 
Working Group, 1992; Sackett et al., 1996; Chambless & Hollon, 1998).  
Several evidence grading systems have emerged over the past decades for issuing clinical 
recommendations in both psychotherapy research (see, e.g., Chambless & Ollendick, 2001) and 
clinical medicine (e.g. Atkins et al., 2004; OCEBM Working Group, 2011). Nevertheless, to date 
there has been no consensus on standards for clinical efficacy determination in the hypnosis 
field, thereby preventing the field from issuing a clear and unequivocal message about the 
efficacy of treatment applications. This shortcoming has potentially  played a role in limiting the 
utilization of hypnosis as a treatment option in healthcare in society in general.  
Perhaps one reason for the lack of take-up of the above-mentioned evaluation methods in 
our field might be that there are some field-specific considerations in clinical hypnosis research 
that are not clearly addressed in these evidence grading systems. For example, it is not clear from 
these systems whether and how to take into consideration the hypnotizability of participants in 
the trials, and which studies can be taken into consideration in the efficacy assessment, when 
there are so many different intervention variants. Furthermore, double-blind placebo-controlled 
designs are held as the gold standard in most of the previous rating systems for demonstrating 
efficacy. However, the central role of expectancy in hypnotic effects demonstrated in both 
laboratory and clinical trials (e.g., Lynn et al., 2008) makes it unclear whether these types of 
designs would convey the same information about efficacy as in medical research.   
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Thus, in order to facilitate the adoption of efficacious clinical hypnosis interventions in 
healthcare, there is an urgent need for a consensus-based system for issuing evidence-based 
clinical recommendations about applications of clinical hypnosis. The recognition of this need 
led to the formation of the Hypnosis Efficacy Task Force. 
The Hypnosis Efficacy Task Force 
In 2018, in recognition of the unmet need for efficacy standards in field of hypnosis, the 
Society for Clinical and Experimental Hypnosis (SCEH) initiated an organizational meeting on 
this issue at the triennial Congress of the International Society of Hypnosis (ISH) in Montréal, 
Canada. Shortly thereafter, six major hypnosis societies agreed to co-sponsor an international 
“Task Force for Establishing Efficacy Standards for Clinical Hypnosis”. Co-sponsors included 
SCEH, the American Society of Clinical Hypnosis, the American Psychological Association 
Division 30, the Milton Erickson Foundation, the National Pediatric Hypnosis Training Institute, 
and the International Society of Hypnosis.   
Zoltan Kekecs and Donald Moss agreed to convene and guide the Task Force, which was 
composed of nine selected researchers from Hungary, the US, the UK, and Italy who committed 
to participating in the Task Force deliberations. The participants are the authors of this paper: 
Giuseppe De Benedittis, Gary Elkins, Zoltan Kekecs, Donald Moss, Olafur S. Palsson, Philip D. 
Shenefelt, Devin B. Terhune, Katalin Varga, and Peter Whorwell. In addition, additional 
researchers agreed to serve as consultants to the Task Force: Mark Jensen, Elvira Lang, and 
David Patterson. 
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The Task Force defined and pursued three objectives: 1) to establish guidelines for the 
assessment of the efficacy of hypnosis applications, based on methodological criteria; 2) to 
develop recommendations for best practices in future outcomes research on clinical hypnosis; 
and 3) to conduct an international survey of clinicians, researchers, and students in the field of 
hypnosis, to provide the most comprehensive picture to date on current practices and views in 
this community.  
This paper will introduce the Hypnosis Efficacy Task Force’s Guidelines for the 
Assessment of Efficacy of Clinical Hypnosis Applications that resulted from the work on the 
first objective. These guidelines are not intended to serve as a stand-alone system for efficacy 
assessment. Instead, they serve as recommendations for applying already existing comprehensive 
efficacy rating systems to data in the field of clinical hypnosis. The sections that follow provide a 
detailed description of the guidelines, the methods through which they were derived, and where 
appropriate, some rationale on why a specific guideline was chosen.    
Methods 
The Guidelines listed below are based on discussions in a series of monthly meetings of 
the Hypnosis Efficacy Task Force between February and November 2019. In the first meetings, 
the Hypnosis Efficacy Task Force reviewed existing evidence rating and recommendations 
systems, such as the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system (Guvatt et al., 2008), the OCEBM: Levels of Evidence Table (OCEBM 
Working Group, 2011), and the evidence grading system of the Association for Applied 
Psychophysiology and Biofeedback (AAPB) and the International Society for Neuronal 
Regulation (ISNR) (LaVaque et al., 2002; Tan et al., 2016), as well as the APA Division 12 
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Empirically Supported Therapies (ESTs) rating system (Chambless & Hollon, 1998). Based on 
this initial review, we decided that the GRADE system provides a suitable framework for 
synthesizing evidence and formulating clinical recommendations.  
However, we concluded that additional work was needed to make this system applicable 
in the field of clinical hypnosis to take into consideration important hypnosis-specific research 
features that can influence the assessment of effectiveness, risk of bias, and quality of evidence. 
After this consensus decision, an initial list of recommendations was drafted, which was then 
reviewed, amended, and supplemented by the Task Force in subsequent meetings. The final draft 
of the guidelines was sent to the external consultants -- Mark Jensen, Elvira Lang, and David 
Patterson -- who reviewed the list and recommended improvements. These suggested 
amendments were integrated into the recommendations at subsequent meetings. The final 
wording of the guidelines was reviewed and approved unanimously at the November 26, 2019 
meeting by all members who contributed to formulating the guidelines, namely Giuseppe De 
Benedittis, Gary Elkins, Zoltan Kekecs, Donald Moss, Olafur Palsson, Philip Shenefelt, Devin B. 
Terhune, Katalin Varga, and Peter Whorwell. 
Guidelines for the Assessment of Efficacy of Clinical Hypnosis Applications 
In this section we list the Hypnosis Efficacy Task Force’s Guidelines for the Assessment 
of Efficacy of Clinical Hypnosis Applications. The following recommendations are intended to 
guide researchers who want to assess the accumulated evidence - based on multiple studies - 
about the efficacy of certain applications of clinical and medical hypnosis. The guidelines 
contain recommendations about which methods are thought to be adequate for the assessment of 
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efficacy and quality of evidence and highlight certain important features that should be taken into 
consideration during an efficacy assessment.  
1. Establishment of efficacy should be based on a sufficiently recent systematic 
review matching the highest quality standards, including multiple studies 
supporting the effectiveness of the treatment application. Whenever possible, the 
systematic review should be accompanied by a quantitative synthesis of the effect 
sizes (such as a meta-analysis) at the time of publication. The systematic review 
on which the efficacy assessment is based needs to be peer-reviewed (a peer 
reviewed journal article or book chapter are both eligible).  
2. GRADE guidelines are endorsed by the Hypnosis Efficacy Task Force to assess 
efficacy (Guyatt et al., 2008a, 2008b, 2008c).  
a. Note: It is possible that there is or will be in the future a system other than 
the GRADE that is appropriate to assess efficacy. Thus, the use of other 
systems is not specifically excluded. Nevertheless, the system must be 
comparable in sophistication and reliability to the GRADE system and 
must account for all potential biases considered in the GRADE system.  
3. The sample size, effect size (and associated confidence intervals), and clinical 
significance should be taken into consideration when evaluating efficacy. Thus, 
the systematic review(s) and meta-analysis(es), on the basis of which efficacy is 
determined, should highlight all of this information. Furthermore, where relevant, 
data from non-completers within research studies should also be taken into 
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consideration when assessing efficacy (for example data reported via intention-to-
treat [ITT] analysis). 
4. The assessment of hypnotizability is encouraged in clinical hypnosis studies 
(Jensen et al., 2017), since it can inform about the underlying mechanisms 
producing any therapeutic effects but is not required to establish the efficacy of a 
hypnosis-based treatment. 
5. Blinding of the participants/patients and the interventionists to group allocation is 
aspirational but is not required to establish efficacy of a hypnosis-based treatment. 
a. Note: However, establishing that a hypnosis-based intervention has 
benefits over a well-matched placebo/sham control condition, or an 
already established active treatment condition, in a study where 
participants were blinded to group allocation can strengthen inferences 
regarding the specificity of the intervention.  
6. Blinding of data collectors with respect to group allocation and/or hypnotizability 
level of the participant reduces the risk of experimenter biases (Barber, 1976). 
This should be taken into consideration in the risk of bias assessment and when 
determining the quality of the evidence (see also Holman et al., 2015).  
7. Blinding of those responsible for the statistical analysis with respect to group 
allocation can decrease the risk of experimenter biases. (Automation of the 
analysis or exact pre-registration of the analysis plan can serve the same purpose). 
This should be taken into consideration in the risk of bias assessment and when 
determining the quality of the evidence.  
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8. The efficacy rating of hypnosis applications should be based on publications that 
meet the following criteria: 1) the intervention (or a component of a complex 
intervention) is labeled by the authors of the paper as “hypnosis” or one of its 
close synonyms (“hypnotic treatment”, “hypnotherapy”, etc.); and 2) the 
description of the intervention does not describe a process that expert reviewers 
would not categorize as hypnotic, under current consensus (for a consensus-based 
definition, see, e.g., Elkins et al., 2015).  
a. Note: It is not necessary that the intervention has been labelled as 
“hypnosis” to the participants of the study, but the labeling of the 
intervention to participants should be considered as a possible moderator 
in the meta-analysis, since labeling the intervention as hypnosis to 
participants has been found to increase effect size (Gandhi & Oakley, 
2005). 
9. In order to warrant the highest quality of evidence rating, the studies supporting 
the efficacy of the treatment should be conducted by at least two independent 
research groups, or at least one of the studies supporting efficacy should be a 
multi-center clinical trial. 
10. For chronic or enduring conditions, efficacy needs to be demonstrated at a long 
follow-up assessment which is considered clinically appropriate for the given 
condition to warrant the highest quality of evidence rating. For many conditions, 
such as chronic pain, this would be six months or longer. 
Discussion 
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The list of recommendations presented above is deliberately concise in order to ensure its 
practical usefulness for researchers. Below we discuss some of the considerations that went into 
formulating these guidelines and other topics relevant to fully understand them.  
GRADE 
The efficacy assessment guidelines put together by the Hypnosis Efficacy Task Force 
endorse the GRADE system for assessing the level of evidence for efficacy, and for formulating 
clinical recommendations. The reason for this choice was two-fold. On the one hand, this system 
seemed well-developed and comprehensive. One distinguishing feature of GRADE is that it 
includes a systematic review of the research studies assessing the effectiveness of the clinical 
application, and making a decision based on all studies found in the systematic review combined, 
while most other systems only require a certain number of studies showing efficacy for the 
efficacy rating. On the other hand, GRADE is currently the most accepted clinical 
recommendation system in medical research, with many high quality journals including it in their 
standard submission guidelines. Since clinical hypnosis has a great number of medical 
applications, it is an added advantage that recommendations made using the GRADE system 
would be easier to understand and seen as more credible for medical professionals and decision 
makers than those made using systems they are less familiar with, such as the Division 12 ESTs 
system primarily devised for psychotherapy applications. Tolin and colleagues (Tolin, McKay, 
Forman, Klonsky & Thombs, 2015) provide a good overview of the criticisms of the Division 12 
ESTs system in its original form, and rationale for why the ESTs need to be updated in a way 
that they are based on a systematic review of the literature and on the GRADE system.    
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Conducting a GRADE review is time-consuming and needs to be planned prospectively 
before the systematic review is conducted. Thus, before conducting evaluation of the efficacy of 
a hypnosis application, researchers need to familiarize themselves with GRADE. This can be 
done by following instructions on the GRADE Working Group’s website: 
https://www.gradeworkinggroup.org/, and by reading the main publications on the method 
(Balshem et al., 2011; Guyatt et al., 2008a; Guyatt et al., 2008b; Guyatt et al., 2008c; Guyatt et 
al., 2011a; Guyatt et al., 2011b). For a concise overview of the GRADE system, see 
https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/ by Siemieniuk and Guyatt 
(n.d.).  The readers can also find good guidance about how Cochrane Reviews and GRADE 
recommendations can be integrated by the Cochrane GRADEing Methods Group (Schünemann, 
et al., 2019). 
The following is a high-level summary of the GRADE system: The researchers conduct a 
systematic review of the research studies conducted on the clinical application of interest and, 
following specific instructions, produce two main outcomes: 1) they state the quality of evidence 
supporting the efficacy of the application, and 2) they issue a recommendation about the use of 
the intervention for treating the symptom or condition. The quality of the evidence is rated on a 
four-level scale (“very low,” “low,” “moderate,” “high”) depending on a number of factors such 
as study limitations, consistency and precision of results, directness of evidence, publication bias, 
and magnitude of the effect. The meaning of the different quality of evidence ratings are 
provided in Table 1, based on Siemieniuk and Guyatt (2021). In a review only including 
randomized controlled trials, the quality of evidence rating starts out at high but can be down-
graded if there are concerns related to risk of bias in the studies, imprecision of effect estimates, 
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inconsistency of the findings among the reviewed studies, indirectness of evidence due to the 
studied populations being not directly relevant, or publication bias. The quality of evidence can 
be up-graded if the studies indicate a very large magnitude of effect, if there is evidence for dose-
response in the studies, or when residual confounding is likely to decrease rather than increase 
the magnitude of effect (for more details, see Box 1. and Schünemann, Brozek, Guyatt & 
Oxman, 2013). A “high” quality of evidence rating is very rarely given due to the high standards 
this requires, and we do not anticipate that at present many hypnosis applications would receive 
this rating, but as new, high-quality research evidence is accumulated, more and more 
applications may reach this level.  
In addition to the quality of evidence rating, a GRADE recommendation regarding an 
intervention can be either “strong recommendation” or “weak recommendation” to use the 
treatment, or the reviewers can issue a strong or weak recommendation against the use of the 
treatment. When determining the level of recommendation, the reviewers need to consider 
factors such as balance between desirable and undesirable effects, quality of evidence, values 
and preferences of patients, and costs of treatment. Table 2. provides more details about the 
influence of these factors on the strength of recommendation based on Guyatt et al. (2008a). For 
example, if it is clear that the benefits far outweigh the risks and virtually all informed patients 
would make the same choice, a “strong recommendation” would be issued. In contrast, if 
considering the evidence, most informed patients would choose to use the treatment, but a 
substantial number would not choose it for some reason, so patient values and preferences will 
play a crucial role in the final decision by the patient, a “weak recommendation” would be issued 
(Andrews et al., 2013). A “strong recommendation” may be issued even if the quality of 
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evidence is not “high”. Rather, a recommendation level will depend on the balance between the 
benefits and the costs and risks associated with the application. In addition, it should be noted 
that applications with a “weak recommendation” are still recommended. It is just that personal 
values and preferences tend to play a larger role in choosing the treatment compared to 
treatments with “strong recommendation”, which are basically “no-brainers”. 
Despite our efforts we did not find another assessment system that would be comparable 
in sophistication and sensitivity to bias to the GRADE system, so currently this is the only 
system that is endorsed by the Task Force. If another system is used, it must be comparable in 
sophistication and reliability to the GRADE system and must account for all of the potential 
biases that are considered in the GRADE system. 
Clinical significance 
It is important to note that clinical recommendations are not primarily based on statistical 
significance. Demonstrating statistically significant evidence supporting the treatment effect is a 
necessary but not a sufficient condition for recommending the use of the treatment. Even a very 
small and clinically meaningless effect can be statistically significant depending on the size of 
the sample and the variability in the population. Thus, aside from statistical significance, the 
reviewers also have to consider the clinical significance of the treatment effects. Judging whether 
the treatment effect constitutes a clinically meaningful change requires specialized knowledge 
about the patient population, the illness or problem being treated, as well as the different 
measures used to assess the clinical outcomes and how these compare to each other. In some 
cases there might be published guidelines about what constitutes a clinically meaningful 
improvement (see e.g. Sloman, Wruble, Rosen & Rom, 2006), in other cases this might require 
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the involvement of a clinical expert on the topic. For more information on clinical significance, 
see Crosby, Kolotkin & Williams (2003) and Lambert & Bailey (2012). 
Pre-registration 
Pre-registration is the act of depositing the research plan and research hypotheses in a 
trial registry or other repository before data collection is started. This deposited research plan 
must be available for other researchers, to help them assess the similarities and differences of the 
pre-registration and the post-data collection report. (Pre-registration should not be confused with 
“Registered Reports,” where the manuscript is submitted to a journal, peer reviewed, and 
accepted for publication before data collection starts, or publishing a trial protocol, where the 
research protocol is published in a journal as a separate paper before data collection stars) (for 
additional insight and context, see Nosek et al., (2018). 
Pre-registration is one of the best practice methodological tools recommended to mitigate 
researcher- and publication-bias (Nosek et al., 2018). The Hypnosis Efficacy Task Force realizes 
the usefulness of pre-registration and recommends its use in laboratory and clinical trials. There 
are two main reasons for the exclusion of pre-registration in the current efficacy guidelines, both 
of which stem from the fact that pre-registration is a relatively new tool in the fields of medicine 
and social sciences. Firstly, this means that there is not yet enough data regarding the impact of 
pre-registration on researcher and publication biases. Secondly, most studies establishing the 
efficacy of clinical applications of hypnosis were conducted at a time when pre-registration was 
not yet a standard research practice. Nevertheless, this might soon change since there is a clear 
trend in the literature in biomedicine and social sciences to treat pre-registration as a standard 
requirement for confirmatory research and more and more journals include this in their 
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submission criteria. In future revisions of the recommendations the Hypnosis Efficacy Task 
Force plans to revisit this issue. Until then, the Hypnosis Efficacy Task Force advocates strongly 
for the pre-registration of new studies and will regard pre-registration as a marker for reduced 
risk of bias. 
Specificity of the Hypnosis-based Treatment 
As stated in the guidelines, the assessment of hypnotizability is not required for 
establishing efficacy of a hypnosis-based treatment. The Hypnosis Efficacy Task Force notes 
that it is important to establish that there is a correlation between a treatment effect and 
hypnotizability. Such a correlation is informative as it can provide valuable information 
regarding whether the effect is attributable to suggestion or another factor (e.g., motivation). 
Bowers’ doctrine, for example, holds that any effect that is not related to hypnotizability should 
not be labeled as a hypnotic effect (Woody & Barnier, 2008). However, establishing such a 
correlation is not a necessary requirement for a treatment to be deemed efficacious. Rather, 
efficacy is a property of the treatment package as a whole and does not require specificity to any 
mechanism. The specificity of the treatment is not of primary concern unless alternative 
treatments have a better benefit to cost ratio. In fact, a meta-analysis by Montgomery and 
colleagues revealed that the relationship between hypnotizability and treatment outcomes was 
small (Montgomery et al., 2011). Nevertheless, it is recommended to assess hypnotizability in 
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Blinding (masking) of participants/patients and research staff administering the treatment 
is often considered a key aspect in medical trials to minimize bias due to expectancy and 
establish that the treatment effect is specific to the proposed effective component of the 
treatment, for example the specific drug (Shadish et al., 2002). However, as mentioned above, 
specificity is less of a concern when establishing efficacy. It is true that specificity can affect the 
costs of a treatment. For example, if the active drug component turns out to be inert and the 
effect is mainly due to response expectancy, costs can be reduced. However, expectancy plays a 
central role in psycho-social interventions such as hypnosis (Kirsch, 1994; Kirsch, 2005), and it 
can be thought of as an active ingredient. Accordingly, the use of classic double-blind placebo-
controlled designs from clinical medicine are controversial and difficult to apply in this field 
(Kirsch, 2005; Parloff, 1986). Nevertheless, certain types of blinding of participants can still be 
possible using minimally effective control conditions (Jensen & Patterson, 2005) and even sham 
conditions (Barton et al., 2017; Kendrick et al., 2013; Sliwinski & Elkins, 2013), which might be 
beneficial in mitigating some experimenter biases and demand-biases, and also in obtaining  a 
better understanding of the role of expectancy in the treatment effect. 
On the other hand, blinding of other people involved in the study such as data collectors, 
outcome assessors, and data analysts is recommended to reduce experimenter biases, and the 
absence of proper blinding of these individuals should be considered in the risk of bias 
assessment.  
Which Interventions Can Be Considered as Hypnosis-based Treatments? 
What types of interventions can, or should a researcher include in a systematic review 
when conducting efficacy assessment of hypnosis-based treatments? Even though there have 
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been multiple attempts at defining hypnosis (e.g. Green et al., 2005; Wagstaff, 1998; Elkins et 
al., 2015), the boundaries are still unclear about what can and cannot be called a hypnosis-based 
intervention. For example, interventions such as guided imagery, autogenic training, therapeutic 
suggestions, and Ericksonian conversation etc. may be considered hypnosis-based treatments by 
some, but not by others. This introduces a certain amount of degrees of freedom for researchers 
in their inclusion criteria for studies. These degrees of freedom can be sources of bias. For 
example, certain types of treatments might be included because there are studies with good 
reported effects in the literature, whereas others might be excluded because of poor results, 
resulting in an overestimation of the effect size. To overcome this bias, the Task Force has 
decided to issue a recommendation about what can be regarded as a hypnosis-based treatment for 
the purposes of efficacy assessment of hypnosis-based interventions. We wanted to allow for as 
much researcher flexibility as possible whilst remaining responsive to changes in the field 
regarding the definition of hypnosis and still limiting possibilities for result-based sampling bias. 
Accordingly, we recommend that for a study to be included in the efficacy assessment review, 
the intervention used needs to have been labeled in the paper as “hypnosis” or a close synonym 
(e.g., “hypnotic treatment,” “hypnotherapy”). In addition, the intervention should align with the 
current consensus among experts about what can be categorized as hypnosis (for a consensus-
based definition, see, e.g., Elkins, Barabasz, Council, & Spiegel, 2015). An intervention can be 
considered a hypnosis-based intervention even if hypnosis is an adjunct to another intervention, 
as long as at least one part of the complex intervention is identified as hypnosis by the authors of 
the paper and it meets the above criteria.   
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Importantly, this recommendation does not specify how an intervention should be 
presented to the participants of a study. So, even if the intervention is not labeled directly as 
hypnosis to the participants, but the study meets the two foregoing criteria, it can be included in 
the efficacy assessment. Nevertheless, it is important to note that the label used when presenting 
an intervention to participants influences efficacy, and that the label “hypnosis” seems to have a 
considerable positive effect (see, e.g., Gandhi & Oakley, 2005; Schoenberger, Kirsch, Gearan, 
Montgomery & Pastyrnak, 1997). Thus, pooling of studies where the intervention is labeled as 
hypnosis for participants with other studies where other labels are used is discouraged, since it is 
likely that interventions with the hypnosis label will have larger effect size. Rather, studies with 
different labels can be treated separately, and this factor can be included in a moderation analysis 
in the meta-analysis. The recommendations of the Task Force could be useful for researchers 
who want to make clinical recommendations for other types of interventions similar to hypnosis, 
such as guided imagery, autogenic training, therapeutic suggestions, and Ericksonian 
conversation. 
Importance of Independent Replication 
Independent replication is held as the gold standard for verifying the reliability of 
scientific claims (Frank & Saxe, 2012). Recent large-scale replication efforts indicate that only 
about 50% of findings reported in the top tier journals of psychological science are reproducible, 
even with the direct involvement of the original authors (Baker, 2015; Camerer et al., 2018; 
Open Science Collaboration, 2015; Owens, 2018). This demonstrates that it is unwise to base 
practical recommendations on a single research report, however prestigious the journal it was 
reported in. Thus, the Task Force recommends that the highest level of evidence rating should 
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only be issued for clinical applications that have been demonstrated to be effective by at least 
two independent research teams, or by at least one multi-center clinical trial. 
Treatment Fidelity 
Treatment fidelity means that the intervention is executed consistently as intended by all 
intervention deliverers (therapists) in the study. This is an important aspect of clinical research 
that can have a great influence on the effectiveness of the intervention measured in the study. 
Treatment fidelity can be increased through training and supervision of therapists, clear and 
comprehensive treatment manuals, and using intervention protocols that are easy to execute 
consistently. Furthermore, the experience level and allegiance of the therapist to the interventions 
used can also influence as-intended treatment implementation. The Task Force highly 
recommends reporting this information in papers on individual clinical trials. Ideally, treatment 
fidelity should be taken into consideration during the efficacy assessment, and studies with 
demonstrated treatment fidelity should be weighted higher than other studies or studies where 
problems are identified in treatment fidelity. However, currently the transparent reporting of 
these factors is very uncommon in research papers, so it is hard to incorporate these in the 
efficacy assessment process today. That is why the list of recommendations do not include this 
aspect currently. The new Cochrane Risk of Bias Tool (RoB 2) incorporates a new risk of bias 
category “Bias due to deviation from intended interventions” where intervention fidelity is taken 
into account especially when blinding of participants and therapists is not possible (Munder & 
Barth, 2018; Sterne, et al. 2019). Since the RoB 2 is a part of the GRADE assessment, reviewers 
can already incorporate issues related to deviations from intended protocols into their efficacy 
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assessment. As the reporting of factors contributing to treatment fidelity will become more 
common, the Task Force may include a recommendation regarding this aspect of clinical trials.      
Summary 
The Hypnosis Efficacy Task Force was assembled in 2018, with the collaboration of six 
North American and international hypnosis organizations. Nine leaders in the field of hypnosis 
participated in monthly Task Force meetings from 2019 through 2021, and five additional 
leaders in the field reviewed the deliberations and recommendations of the Task Force and 
provided guidance. 
The Hypnosis Efficacy Task Force focused on three objectives: 1) Developing a set of 
guidelines for the assessment of the efficacy of hypnosis applications, based on methodological 
criteria, 2) Formulating recommendations for best practices in future outcomes research on 
clinical hypnosis, and 3) Conducting an international survey of clinicians, researchers, and 
students in the field of hypnosis, to provide the most comprehensive picture to date on current 
practices and views. 
This report addresses the first objective, creating guidelines for the assessment of 
efficacy. The Hypnosis Efficacy Task Force recommends that any researcher assessing the 
efficacy of hypnotic interventions for a specific hypnosis application utilize a well-documented 
and widely respected evidentiary standard such as the GRADE system. This report suggests 
several adaptations of the GRADE standards for hypnosis research, based on challenges specific 
to the study of hypnosis. The Task Force report includes ten specific Guidelines for the 
Assessment of Efficacy of Clinical Hypnosis Applications. 
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Finally, the report addresses several recurrent issues in hypnosis research: the use of the 
GRADE system, the value of pre-registration of research protocols, the value of including an 
assessment of hypnotizability in outcome research, the challenges of blinding in hypnosis 
research, the question of which interventions as hypnosis in outcome research, and the 
importance of independent replication in outcome research. 
Two additional papers will be forthcoming from the Task Force, the first reporting the 
Task Force recommendations for best practices in future outcomes research in hypnosis, and the 
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Quality of evidence Meaning 
Very low The true effect is probably markedly different from the estimated 
effect 
Low The true effect might be markedly different from the estimated 
effect 
Moderate The authors believe that the true effect is probably close to the 
estimated effect 
High The authors have a lot of confidence that the true effect is similar 





Factors considered during the recommendation 
Strong - The desirable effects greatly outweigh the undesirable effects 
- The quality of evidence is relatively high 
- The values and preferences of patients related to the desirable 
and undesirable effects are clear 
- The cost of treatment is acceptable compared to the risks and 
benefits involved 
Weak - The difference between the desirable and undesirable effects is 
not large enough to warrant a strong recommendation 
- The quality of evidence supporting clinically meaningful 
beneficial effects is not high enough to warrant a strong 
recommendation 
- There is uncertainty about, or variability in, values and 
preferences related to the weight of desirable and undesirable 
effects 
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 Box 1. GRADE Quality of evidence rating 
Box 1. GRADE Quality of evidence rating 
 
There are four levels for the quality of evidence rating in GRADE: very low, low, 
moderate, and high.  
 
Randomised trials begin as high quality evidence and observational studies as low 
quality evidence, and this initial rating is upgraded or downgraded based on the factors 
below: 
 
Quality of evidence may be downgraded due to the following factors: 
- Risk of bias: There is evidence for risk of bias in the design of the studies 
included in the review or other important study limitations. 
- Inconsistency: There is considerable heterogeneity in the effects reported by the 
studies in the review. 
- Indirectness: The studies in the review don’t include the relevant interventions 
(only similar interventions), and/or if the studies don’t include the populations 
or outcomes of primary interest. 
- Imprecision: There is uncertainty about the size of the effect, for example 
because the studies include relatively few participants and/or events and thus 
have a wide confidence interval around the estimate of the effect. 
- Publication bias: There is evidence for selective publication of studies resulting 
in a systematic bias in the effect estimates. 
 
Quality of evidence may be upgraded due to the following factors: 
- Large magnitude of an effect: There is reliable evidence that the effects are 
large (risk ratio over 2). 
- Dose-response gradient: There is reliable evidence that an increase in the dose 
of the intervention leads to an increase in the effects. 
- Effect of plausible residual confounding: All residual confounders are expected 
to decrease the magnitude of the effect. Unmeasured determinants or 
moderators of the effect (residual confounders) can be distributed unequally 
between intervention and control groups in observational studies. In some cases 
an observational study is conducted in a way that only such unaccounted 
confounders remain that would result in an underestimate of an apparent 
treatment effect.   
 
For more details on how the above mentioned factors should be used in determining 
quality of evidence, see the Quality of evidence section in the GRADE Handbook. 
(Schünemann, Brozek, Guyatt & Oxman, 2013). 
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